



Rydym yn croesawu gohebiaeth yn y Gymraeg neu'r Saesneg. Atebir gohebiaeth Gymraeg yn y Gymraeg, ac ni fydd hyn yn arwain at oedi. We welcome correspondence in Welsh or English. Welsh language correspondence will be replied to in Welsh, and this will not lead to a delay.

Cais Rhyddid Gwybodaeth / Freedom of Information request **Ein Cyf / Our Ref: 22-H-037**

Please note that we have provided this information for the period January to June 2022.

You asked:

1. Does your Health Board treat myelofibrosis? If not, which other trust do you refer these patients to?

Yes, Swansea Bay Health Board treats myelofibrosis.

2. Please provide the total number of patients treated in the last 6 months (or the latest 6 months data you have available) for myelofibrosis (ICD10 code D47.4).

In the period 01.01.22 to 31.06.22, 9 patients were admitted 54 times where Myelofibrosis was the primary reason for their admission to hospital.

a. How many of these patients were above age 65?

We are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

However, we can advise that 11 of the 54 admissions were for patients over the age of 65.

3. How many myelofibrosis patients were treated in the past 6 months with Ruxolitinib?

10 patients (please note that our systems do not separate myelofibrosis from other myeloproliferative disorders (MPD) therefore this total is for all MPD patients



not just those with myelofibrosis).

4. How many myelofibrosis (ICD10 code D47.4) patients has your Health Board diagnosed in the past 3 years?

<5 patients

Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

a. Of these patients, how many were treated in the past 6 months (or the latest 6 months data you have available) with:

- **Hydroxyurea** - 0
- **Fedratinib** - 0
- **Received No Treatment** – not applicable

5. Does your Health Board participate in any clinical trials for the treatment of myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part.

SBUHB have not participated in any clinical trials for the treatment of myelofibrosis in the time period specified.

